0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

Mycophenolate Mofetil to Treat Neuromyelitis Optica Is It Time for a Randomized Trial?

Bruce Cree, MD, PhD, MAS1
[+] Author Affiliations
1Department of Neurology, Multiple Sclerosis Center, University of California San Francisco
JAMA Neurol. 2014;71(11):1354-1357. doi:10.1001/jamaneurol.2014.2359.
Text Size: A A A
Published online

Extract

Should clinical trials of disease-modifying therapies be conducted for neuromyelitis optica (NMO)? If so, how should these trials be designed and which therapy tested? Because of its relative scarcity as well as the clinical overlap with multiple sclerosis (MS), randomized clinical trials of NMO treatments have not been undertaken. Hence, there are no therapies that are proved to reduce the frequency of relapses in NMO and alleviate the accumulation of disability. Open-label studies suggested that immune suppressants, such as azathioprine (AZA),1 rituximab,2 and mycophenolate mofetil (MMF),3 may reduce the frequency of relapses in NMO. In this issue, Huh and colleagues4 report their experience treating 58 patients with NMO using MMF. To my knowledge, this is the largest study of MMF treatment in patients with NMO reported thus far. Huh and colleagues observed that, following MMF treatment, there was a decline in the annualized relapse rate and that disability, as measured by the Expanded Disability Status Scale (EDSS), improved. In particular, this study suggests efficacy of MMF in patients with NMO who have not been treated with other immune therapies. This study also suggests that treatment with MMF is associated with fewer adverse effects than AZA, a widely used, broad-spectrum immune suppressant. These observations complement and add to the existing publications of similar uncontrolled, open-label studies, suggesting the therapeutic efficacy of immune suppressants in treating NMO.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

548 Views
2 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
Jobs
brightcove.createExperiences();